SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma

Jacqueline E. Noll, Duncan R. Hewett, Sharon A. Williams, Kate Vandyke, Chung Kok, Luen B. To, Andrew C W Zannettino

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


Multiple myeloma (MM), a hematological malignancy characterized by the clonal growth of malignant plasma cells (PCs) in the bone marrow, is preceded by the benign asymptomatic condition, monoclonal gammopathy of undetermined significance (MGUS). Several genetic abnormalities have been identified as critical for the development of MM; however, a number of these abnormalities are also found in patients with MGUS, indicating that there are other, as yet unidentified, factors that contribute to the onset of MM disease. In this study, we identify a Samsn1 gene deletion in the 5TGM1/C57BL/KaLwRij murine model of myeloma. In addition, SAMSN1 expression is reduced in the malignant CD138. + PCs of patients with MM and this reduced expression correlates to total PC burden. We identify promoter methylation as a potential mechanism through which SAMSN1 expression is modulated in human myeloma cell lines. Notably, re-expression of Samsn1 in the 5TGM1 murine PC line resulted in complete inhibition of MM disease development in vivo and decreased proliferation in stromal cell-PC co-cultures in vitro. This is the first study to identify deletion of a key gene in the C57BL/KaLwRij mice that also displays reduced gene expression in patients with MM and is therefore likely to play an integral role in MM disease development.

Original languageEnglish
Pages (from-to)572-585
Number of pages14
JournalNeoplasia (United States)
Issue number7
Publication statusPublished or Issued - 2014

ASJC Scopus subject areas

  • Cancer Research

Cite this